Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASM8 in Moderate to Severe Asthma
NCT01380236Phase 2Withdrawn
- Sponsor
- Syntara Limited
- Start
- Nov 2011
- Primary completion
- Jun 2012
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
01
Overview
A Phase 2 trial of ASM8 in asthma, sponsored by Syntara Limited. Planned start Nov 2011; status: withdrawn.
02
Drugs
ASM8
03
Conditions
asthma
Beyond the preview
Go deeper on NCT01380236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01380236.